Prime Medicine, Inc.
PRME · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.20 | -0.61 | -0.11 | 0.11 |
| FCF Yield | 0.00% | -13.47% | -19.69% | 4.17% |
| EV / EBITDA | -17.34 | -7.47 | -5.72 | -4.81 |
| Quality | ||||
| ROIC | -15.09% | -21.17% | -17.42% | -16.80% |
| Gross Margin | 0.00% | -67.17% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.69 | 0.79 | 0.94 | -0.38 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,814,695.74% | 1,705,418.40% | 1,566,662.23% | 1,439,420.16% |
| Free Cash Flow Growth | 0.00% | 16.18% | -454.77% | 153.16% |
| Safety | ||||
| Net Debt / EBITDA | -0.87 | -1.28 | -0.58 | 3.33 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -298.26 | -529.68 | -594.99 |